Literature DB >> 23432684

The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia.

Sweta Gupta1, Azfar-E-Alam Siddiqi, J Michael Soucie, Marilyn Manco-Johnson, Roshni Kulkarni, Heidi Lane, Robina Ingram-Rich, Joan C Gill.   

Abstract

This study prospectively compared the effect of secondary prophylaxis to episodic treatment on target joint (TJ) range of motion (ROM), number of joint haemorrhages and new TJ development in patients with moderate or severe haemophilia. Two-hundred and eighty-six males, 17% in prophylaxis, 83% in episodic treatment group, participating in the Centers for Disease Control and Prevention's Universal Data Collection project, fulfilled inclusion criteria: age >2 years at enrollment, free of TJs at enrollment, developed at least one TJ after enrollment, and received either prophylaxis or episodic treatment continuously for two follow-up visits after TJ development. The outcomes of interest - percentage change in TJ ROM, number of joint haemorrhages and new TJ development, were modelled using multivariate linear, Poisson and logistic regression techniques respectively. Individuals who received secondary prophylaxis in comparison to episodic treatment were younger at TJ development (P < 0.01); there was no difference in the decrease in TJ ROM between the two groups (P = 0.9). Factors significantly associated with a higher rate of haemarthroses included episodic treatment, severe haemophilia, age >5 years at TJ development, obesity and inhibitor negative status. Secondary prophylaxis significantly decreased haemarthroses but was not associated with a significant improvement in TJ ROM or with new TJ development.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23432684      PMCID: PMC4494109          DOI: 10.1111/bjh.12267

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  28 in total

1.  The principal results of the International Immune Tolerance Study: a randomized dose comparison.

Authors:  Charles R M Hay; Donna M DiMichele
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

2.  2000 CDC Growth Charts for the United States: methods and development.

Authors:  Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal:  Vital Health Stat 11       Date:  2002-05

3.  The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A.

Authors:  J M Soucie; C Wang; A Siddiqi; R Kulkarni; M Recht; B A Konkle
Journal:  Haemophilia       Date:  2011-03       Impact factor: 4.287

4.  Immature articular cartilage is more susceptible to blood-induced damage than mature articular cartilage: an in vivo animal study.

Authors:  Michel J J Hooiveld; Goris Roosendaal; Marieke E Vianen; H Marijke van den Berg; Johannes W J Bijlsma; Floris P J G Lafeber
Journal:  Arthritis Rheum       Date:  2003-02

5.  Pathogenesis of haemophilic synovitis: clinical aspects.

Authors:  W K Hoots; N Rodriguez; L Boggio; L A Valentino
Journal:  Haemophilia       Date:  2007-11       Impact factor: 4.287

6.  Blood safety monitoring among persons with bleeding disorders--United States, May 1998-June 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2003-01-03       Impact factor: 17.586

7.  Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.

Authors:  A Tagliaferri; M Franchini; A Coppola; G F Rivolta; C Santoro; G Rossetti; G Feola; E Zanon; A Dragani; P Iannaccaro; P Radossi; P M Mannucci
Journal:  Haemophilia       Date:  2008-06-05       Impact factor: 4.287

Review 8.  Blood-induced joint disease: the confluence of dysregulated oncogenes, inflammatory signals, and angiogenic cues.

Authors:  Leonard A Valentino; Narine Hakobyan; Candace Enockson
Journal:  Semin Hematol       Date:  2008-04       Impact factor: 3.851

9.  Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.

Authors:  P Collins; A Faradji; M Morfini; M M Enriquez; L Schwartz
Journal:  J Thromb Haemost       Date:  2009-10-11       Impact factor: 5.824

10.  The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.

Authors:  T T Biss; A K Chan; V S Blanchette; L N Iwenofu; M McLimont; M D Carcao
Journal:  Haemophilia       Date:  2008-07-14       Impact factor: 4.287

View more
  5 in total

Review 1.  Key issues in inhibitor management in patients with haemophilia.

Authors:  Keith Gomez; Robert Klamroth; Johnny Mahlangu; Maria E Mancuso; María E Mingot; Margareth Castro Ozelo
Journal:  Blood Transfus       Date:  2013-12-03       Impact factor: 3.443

2.  Men with severe hemophilia in the United States: birth cohort analysis of a large national database.

Authors:  Marshall A Mazepa; Paul E Monahan; Judith R Baker; Brenda K Riske; J Michael Soucie
Journal:  Blood       Date:  2016-03-16       Impact factor: 22.113

3.  Vascular remodeling underlies rebleeding in hemophilic arthropathy.

Authors:  Vikas Bhat; Merissa Olmer; Shweta Joshi; Donald L Durden; Thomas J Cramer; Richard Fw Barnes; Scott T Ball; Tudor H Hughes; Mauricio Silva; James V Luck; Randy E Moore; Laurent O Mosnier; Annette von Drygalski
Journal:  Am J Hematol       Date:  2015-10-08       Impact factor: 10.047

Review 4.  Achieving the unimaginable: Health equity in haemophilia.

Authors:  Mark W Skinner; Diane Nugent; Pam Wilton; Brian O'Mahony; Gerry Dolan; Jamie O'Hara; Erik Berntorp
Journal:  Haemophilia       Date:  2019-11-13       Impact factor: 4.287

5.  Evaluation of CDC's Hemophilia Surveillance Program - Universal Data Collection (1998-2011) and Community Counts (2011-2019), United States.

Authors:  Laura A Schieve; Vanessa R Byams; Brandi Dupervil; Meredith A Oakley; Connie H Miller; J Michael Soucie; Karon Abe; Christopher J Bean; W Craig Hooper
Journal:  MMWR Surveill Summ       Date:  2020-09-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.